Grindr is moving deeper into healthcare, agreeing to purchase PurposeMed for $250 million. The consideration is made up of $190 million in cash plus $60 million in Grindr common stock, with the structure also featuring as much as $70 million more in cash linked to Freddie's 2027 results and payable in 2028. The companies are aiming to wrap it up in the fourth quarter.
This marks the first significant purchase Grindr has made since its 2009 launch. CEO George Arison framed it as a second growth pillar alongside the dating app: "Now we have the next business line that we believe will be as profitable as the core business, and the same size, if not bigger, than what the core business is today."
Freddie launched in Canada in 2020 and entered the U.S. market in 2024. It now reaches patients across every state plus Washington, D.C., and has served more than 55,000 people in the U.S. and Canada. The offering spans virtual care, testing, prescriptions and home delivery.
Grindr plans to weave those services into its app used by millions worldwide. That dovetails with Woodwork, Grindr's LGBTQ health initiative introduced in 2025, which the company wants to build into a meaningful revenue stream next to subscriptions and advertising.
According to Grindr, together the U.S. telehealth and pharmacy businesses should bring in over $400 per active patient each month, amounting to more than $4,800 annually for a person who remains in care for 12 months. At around 50,000 U.S. patients, Arison estimates the business could contribute roughly $240 million in annual revenue.
Management says the platform should lift EBITDA dollars right away, though early investments to expand the U.S. footprint will pressure margins. The company plans to update shareholders in November on capital needs, with Arison expecting margins to improve as volumes scale and ultimately settle near the core app's margin profile of above 40 percent.
The best financial decisions come from understanding the whole picture. Join Market Briefs free and get the full brief each morning.
Asked why buy versus build, Arison said the company could have created a similar service internally, but matching Freddie's scale would likely have taken a couple of years. "You need to build out pharmacies, and you need to have clinicians to be able to fulfill the care that you're providing people," he said. "As you get more patients, then utilization improves, and then you're in a very high margin profile."
Grindr figures roughly 400,000 U.S. users already indicate in their profiles that they take PrEP, with more than 2 million additional U.S. users as potential beneficiaries. PrEP, or pre-exposure prophylaxis, reduces the chance of getting HIV from sex by 99 percent when taken as directed.
Inside Grindr, people will be able to explore PrEP education, check insurance coverage, connect with clinicians, set up testing, secure prescriptions and handle refills.
Investors have been pressing for new revenue levers beyond the core app. Morgan Stanley's Nathan Feather called Grindr underappreciated in a July report, citing a sticky network, heavy engagement and strong profitability. The firm upgraded the shares to overweight from equal weight and lifted the price target to $18 from $16. Shares finished Wednesday at $15.43.
If Grindr executes on patient growth and unit economics while integrating telehealth and pharmacy into its app, you will have a clear yardstick to track against your own expectations for growth, margins and valuation over the next few quarters.
Markets move every day, and most of it never reaches you in time. Get the free Market Briefs daily newsletter and stay ahead of it.
